Jiejun Du

3.4k total citations · 1 hit paper
22 papers, 748 citations indexed

About

Jiejun Du is a scholar working on Epidemiology, Infectious Diseases and Pharmacology. According to data from OpenAlex, Jiejun Du has authored 22 papers receiving a total of 748 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Epidemiology, 8 papers in Infectious Diseases and 8 papers in Pharmacology. Recurrent topics in Jiejun Du's work include Pneumonia and Respiratory Infections (8 papers), Antibiotics Pharmacokinetics and Efficacy (8 papers) and Respiratory viral infections research (7 papers). Jiejun Du is often cited by papers focused on Pneumonia and Respiratory Infections (8 papers), Antibiotics Pharmacokinetics and Efficacy (8 papers) and Respiratory viral infections research (7 papers). Jiejun Du collaborates with scholars based in United States, Russia and France. Jiejun Du's co-authors include Amanda Paschke, Nicholas A. Kartsonis, Joan R. Butterton, Michelle Brown, Robert Tipping, Keith S. Kaye, Helen W. Boucher, Katherine Young, Angela Aggrey and Hee‐Koung Joeng and has published in prestigious journals such as Nature Communications, Gastroenterology and Clinical Infectious Diseases.

In The Last Decade

Jiejun Du

21 papers receiving 738 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections

2019 284 citations J. Motsch, Cláudia Murta de Oliveira et al. Clinical Infectious Diseases profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jiejun Du United States	10	500	390	275	264	131	22	748
Brian Nelson United States	11	396 0.8×	266 0.7×	223 0.8×	226 0.9×	156 1.2×	16	668
Anthony M. Nicasio United States	15	474 0.9×	596 1.5×	371 1.3×	232 0.9×	74 0.6×	18	779
Athina Argyrοpoulou Greece	9	508 1.0×	325 0.8×	248 0.9×	212 0.8×	133 1.0×	15	725
Konstantinos Pontikis Greece	8	582 1.2×	435 1.1×	342 1.2×	146 0.6×	70 0.5×	21	742
Myra W. Popejoy United States	11	431 0.9×	396 1.0×	250 0.9×	228 0.9×	90 0.7×	20	620
Chiara Simona Cardellino Italy	11	540 1.1×	269 0.7×	306 1.1×	221 0.8×	171 1.3×	19	878
Patrick McLeroth United States	8	331 0.7×	239 0.6×	195 0.7×	150 0.6×	93 0.7×	12	554
Rachel V Marini United States	8	407 0.8×	325 0.8×	242 0.9×	183 0.7×	135 1.0×	16	588
Tomefa E. Asempa United States	16	388 0.8×	275 0.7×	163 0.6×	163 0.6×	120 0.9×	48	650
Roberto Andini Italy	14	423 0.8×	289 0.7×	300 1.1×	160 0.6×	281 2.1×	31	850

Countries citing papers authored by Jiejun Du

Since Specialization

Citations

This map shows the geographic impact of Jiejun Du's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jiejun Du with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jiejun Du more than expected).

Fields of papers citing papers by Jiejun Du

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jiejun Du. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jiejun Du. The network helps show where Jiejun Du may publish in the future.

Co-authorship network of co-authors of Jiejun Du

This figure shows the co-authorship network connecting the top 25 collaborators of Jiejun Du. A scholar is included among the top collaborators of Jiejun Du based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jiejun Du. Jiejun Du is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Goswami, Jaya, José F. Cardona, Jorge Caso, et al.. (2025). Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345, an mRNA Vaccine Against RSV, Administered 12 Months Following a Primary Dose in Adults Aged ≥50 Years. Clinical Infectious Diseases. 1 indexed citations

Du, Jiejun, Lan Lan, Archana Kapoor, et al.. (2025). Immune correlates analysis of mRNA-1345 RSV vaccine efficacy clinical trial. Nature Communications. 16(1). 6118–6118. 2 indexed citations

Goswami, Jaya, José F. Cardona, Denise C. Hsu, et al.. (2024). Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial. The Lancet Infectious Diseases. 25(4). 411–423. 11 indexed citations

Puenpatom, Amy, Matthew G. Johnson, Ying Zhang, et al.. (2023). Impact of Molnupiravir Treatment on Patient-Reported COVID-19 Symptoms in the Phase 3 MOVe-OUT Trial: A Randomized, Placebo-Controlled Trial. Clinical Infectious Diseases. 77(11). 1521–1530. 9 indexed citations

Roberts, Jason A., David P. Nicolau, Ignacio Martín‐Loeches, et al.. (2023). Imipenem/cilastatin/relebactam efficacy, safety and probability of target attainment in adults with hospital-acquired or ventilator-associated bacterial pneumonia among patients with baseline renal impairment, normal renal function, and augmented renal clearance. JAC-Antimicrobial Resistance. 5(2). dlad011–dlad011. 10 indexed citations

Martín‐Loeches, Ignacio, Andrew F. Shorr, Marin H. Kollef, et al.. (2023). Participant- and Disease-Related Factors as Independent Predictors of Treatment Outcomes in the RESTORE-IMI 2 Clinical Trial: A Multivariable Regression Analysis. Open Forum Infectious Diseases. 10(6). ofad225–ofad225. 2 indexed citations

Johnson, Matthew G., Julie Strizki, Michelle Brown, et al.. (2023). Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trial. Infection. 51(5). 1273–1284. 23 indexed citations

Strizki, Julie, Jay A. Grobler, Nicholas Murgolo, et al.. (2023). Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial. Infectious Diseases and Therapy. 12(12). 2725–2743. 6 indexed citations

Caraco, Yoseph, Gordon Crofoot, Pablo Andrés Moncada, et al.. (2021). Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized Adults. NEJM Evidence. 1(2). EVIDoa2100043–EVIDoa2100043. 68 indexed citations

10.

Grobler, Jay A., Julie Strizki, Nicholas Murgolo, et al.. (2021). 543. Molnupiravir Maintains Antiviral Activity Against SARS-CoV-2 Variants In Vitro and in Early Clinical Studies. Open Forum Infectious Diseases. 8(Supplement_1). S373–S373. 9 indexed citations

11.

Kaye, Keith S., Helen W. Boucher, Michelle Brown, et al.. (2020). Comparison of Treatment Outcomes between Analysis Populations in the RESTORE-IMI 1 Phase 3 Trial of Imipenem-Cilastatin-Relebactam versus Colistin plus Imipenem-Cilastatin in Patients with Imipenem-Nonsusceptible Bacterial Infections. Antimicrobial Agents and Chemotherapy. 64(5). 19 indexed citations

12.

Losada, Maria C, Jiejun Du, Michelle Brown, et al.. (2020). 1230. Clinical and Microbiologic Outcomes by Causative Pathogen in Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Treated with Imipenem/Cilastatin (IMI)/Relebactam (REL) Versus Piperacillin/Tazobactam (PIP/TAZ). Open Forum Infectious Diseases. 7(Supplement_1). S635–S635. 3 indexed citations

13.

Chen, Luke F., Maria C Losada, Jiejun Du, et al.. (2020). 1460. Imipenem/Cilastatin (IMI)/Relebactam (REL) in Hospital-Acquired/Ventilator-Associated Bacterial Pneumonia (HABP/VABP): Subgroup Analyses of Critically Ill Patients in the RESTORE-IMI 2 Trial. Open Forum Infectious Diseases. 7(Supplement_1). S732–S732.

14.

Tipping, Robert, Jiejun Du, Maria C Losada, et al.. (2020). 1574. Multivariate Regression Analysis to Determine Independent Predictors of Treatment Outcomes in the RESTORE-IMI 2 Trial. Open Forum Infectious Diseases. 7(Supplement_1). S785–S786. 2 indexed citations

15.

Titov, Ivan, Richard G. Wunderink, Antoine Roquilly, et al.. (2020). A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study). Clinical Infectious Diseases. 73(11). e4539–e4548. 143 indexed citations

16.

Motsch, J., Cláudia Murta de Oliveira, V.P. Stus, et al.. (2019). RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections. Clinical Infectious Diseases. 70(9). 1799–1808. 284 indexed citations breakdown →

17.

Kaye, Keith S., Thomas M. File, Helen W. Boucher, et al.. (2018). 1339. Results for the Supplemental Microbiological Modified Intent-to-Treat (SmMITT) Population of the RESTORE-IMI 1 Trial of Imipenem/Cilastatin/Relebactam (IMI/REL) vs. Imipenem/Cilastatin Plus Colistin (IMI+CST) in Patients with Imipenem-Nonsusceptible (NS) Bacterial Infections. Open Forum Infectious Diseases. 5(suppl_1). S409–S409. 3 indexed citations

18.

Sims, Matthew, Patrick McLeroth, Yu‐Chieh Lee, et al.. (2017). Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections. Journal of Antimicrobial Chemotherapy. 72(9). 2616–2626. 126 indexed citations

19.

Haber, Barbara, Graham R. Foster, Kosh Agarwal, et al.. (2017). Elbasvir/Grazoprevir Plus Sofosbuvir in Treatment-Naive and Treatment-Experienced Cirrhotic Patients with Hepatitis C Virus Genotype 3 Infection Treated for 8, 12 or 16 Weeks: Final Results of the C-ISLE Study. Gastroenterology. 152(5). S1061–S1061. 3 indexed citations

20.

Foster, Graham R., Kosh Agarwal, Sulleman Moreea, et al.. (2017). Elbasvir/grazoprevir plus sofosbuvir in treatment-naive and treatment-experienced cirrhotic patients with hepatitis C virus genotype 3 infection treated for 8, 12, or 16 weeks: final results of the C-ISLE study. Journal of Hepatology. 66(1). S503–S504. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact